Effectiveness and safety of a kind of Chinese herbal medicine compound combination in the treatment of portal hypertensive gastropathy in cirrhosis:protocol for a clinical study
- Conditions
- portal hypertensive gastropathy in cirrhosis
- Registration Number
- ITMCTR2100004509
- Lead Sponsor
- Kailuan General Hospital, Tangshan, Hebei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
(1) Comply with the diagnostic standards of Western medicine PHG in cirrhosis.
(2) The age is between 18-75 years old.
(3) Patients with no or small ascites, no upper gastrointestinal bleeding and hepatic encephalopathy.
(4) In the near future, people who take vasoactive drugs such as cardiotonic, nifedipine, nitrates and diuretics need to stop drugs for more than one week, and then observe the indexes after stabilization.
(5) Those who have voluntarily signed the informed consent.
(1) Patients with severe diseases such as malignant hypertension, severe arrhythmia, acute myocardial infarction, cerebrovascular accident, etc.
(2) Patients with acute infection, trauma, surgery, diabetic ketoacidosis, and hyperosmolar coma recently.
(3) Patients with severe primary diseases such as brain, liver, kidney and hematopoietic system, mental illness and cognitive dysfunction.
(4) Patients with tumor and other organ failure.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Helicobacter pylori;Somatostatin;C-reactionprotein;Gastroscopy;anti-parietal cell antibody;liver function;
- Secondary Outcome Measures
Name Time Method